TABLE 1.
Clinical trials performed with stem cells in COVID‐19 patients (www.clinicaltrials.gov)
| Trail identification | Official TITLE | Source of stem cell | Dose delivery | Actual or estimated enrollment | Phase | Status |
|---|---|---|---|---|---|---|
| NCT04473170 | Adaptive open‐label study evaluating the safety and efficacy of autologous non‐ hematopoietic peripheral Blood Stem Cells Therapy in COVID‐19 Outbreak in abu dhabi, 2020 (SENTAD‐COVID Study) | Non‐hematopoietic peripheral Blood Stem Cells (NHPBSC) | Inhalation | 146, randomized | 1 | Completed |
| NCT04713878 | A 8‐week trial of Mesenchymal Stem Cells Therapy in patients With COVID‐19 Pneumonia | Mesenchymal stem cells (MSCs) | 1 × 106 cell/kg, day 0, 2, and 4 Intravenously | 21, randomized | Not applicable | Completed |
| NCT04288102 | A phase II, multicenter, randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy and safety of human umbilical cord‐derived Mesenchymal Stem Cells in the treatment of Severe COVID‐19 Patients | Umbilical cord mesenchymal stem cell (UC‐MSCs) | 4 × 107 cells Day 0, 3, and 6 Intravenously | 100, randomized | 2 | Completed |
| NCT04573270 | A pilot phase study evaluating the effects of a single Mesenchymal Stem Cell Injection in patients with suspected or Confirmed COVID‐19 Infection and healthcare providers exposed to coronavirus patients | Human umbilical‐cord‐derived mesenchymal stem cells (hUC‐MSCs) | Intravenously | 40, randomized | 1 | Completed |
| NCT04355728 | Umbilical cord‐derived Mesenchymal Stem Cells for COVID‐19 Patients with acute respiratory distress syndrome (ARDS) | hUC‐MSCs | 106 cells intravenously | 24, randomized | 1 | Completed |
| NCT04522986 | An exploratory study of ADR‐001 in patients with severe pneumonia caused by SARS‐CoV‐2 infection | Adipose‐derived mesenchymal stem cells (AD‐MSCs) | 1 × 108 cells once a week, four times intravenously | 6, N/A | 1 | Completed |
| NCT04535856 | Therapeutic study to evaluate the safety and efficacy of DW‐MSC in COVID‐19 Patients: Randomized, double‐blind, and placebo‐controlled | DW‐MSC | Low‐dose group (5 × 107 cells) 2 vials High‐dose group (1 × 108 cells)4 vials | 9, randomized | 1 | Completed |
| NCT04492501 | Role of investigational therapies alone or in combination to treat moderate, severe and Critical COVID‐19 | Bone marrow stem cells (BM.MSCs) | Single dose of 2 1 × 106 cells/kg | 600, non‐randomized | Not applicable | Completed |
| NCT04345601 | Single donor banked bone marrow mesenchymal Stromal Cells for the treatment of COVID‐19 Induced ARDS: A non‐blinded randomized, controlled study | MSCs | 1 × 108 cells intravenously | 30, randomized | 1 | Recruiting |
| NCT04486001 | COVID‐19 Stem Cell Therapy: A phase I study of intravenous administration of allogeneic Adipose Stem cells | AD‐MSCs | Intravenously | 20, N/A | 1 | Recruiting |
| NCT04625738 | Efficacy of infusions of Mesenchymal Stem Cells From wharton jelly in the moderate to severe SARS‐cov‐2 related acute respiratory distress syndrome (COVID‐19): A phase IIa double‐blind randomized controlled trial | Wharton's jelly derived MSCs | day 0: 1 × 106 cells/kg day 3: 0.5 × 106 cells/kg day 5: 0.5 × 106 cells/kg | 30, randomized | 2 | Not yet recruiting |
| NCT04416139 | Mesenchymal Stem Cells for the treatment of severe acute respiratory distress syndrome due to COVID‐19. Pilot study | MSCs | 1 × 106 cells a single dose Intravenously | 5, non‐randomized | 2 | Recruiting |
| NCT04494386 | Phase 1/2a Study of umbilical cord Lining Stem Cells (ULSC) in patients with ARDS due to COVID‐19 | Umbilical cord Lining Stem Cells (ULSC) | 1 × 108 cells/dose intravenously | 60 estimated, randomized | 2 | Recruiting |
| NCT04366063 | Mesenchymal Stem Cell Therapy for acute respiratory distress syndrome in coronavirus infection: A phase 2‐3 clinical trial | MSCs | Two doses of 1 × 108 (±10%) day 0 and day 2 Intravenously | 60, randomized | 2 and 3 | Recruiting |
| NCT04339660 | Clinical research of human Mesenchymal Stem Cells in the treatment of COVID‐19 Pneumonia | UC‐MSCs | 1×106 cells/kilogram of weight Intravenously | 30, randomized | 1 | Recruiting |
| NCT04400032 | Cellular Immuno‐therapy for COVID‐19 ARDS (CIRCA‐19) | MSCs | 75 ×106 (panel 1) 150 × 106 (panel 2) and 270 × 106 cells intravenously | 21, non‐randomized | 1 and 2 | Recruiting |
| NCT04361942 | Double blind, placebo‐controlled, phase II trial to evaluate safety and efficacy of allogenic mesenchymal Stromal Cells MSV_allo for treatment of acute respiratory failure in patients With COVID‐19 Pneumonia (COVID_MSV) | MSCs | 1× 106 cells/Kg intravenously | 24, randomized | 2 | Recruiting |
| NCT04269525 | Clinical research regarding the availability and safety of UC‐MSCs treatment for serious pneumonia and critical pneumonia caused by the 2019‐nCOV Infection | UC‐MSCs | 3.3 × 107 cell, 3 dose each time on day 1, day 3, day 5, and day 7 Intravenously | 16, N/A | 2 | Recruiting |
| NCT04367077 | A phase 2/3 study to assess the safety and efficacy of MultiStem® therapy in subjects with acute respiratory distress syndrome (ARDS) due to coronavirus disease (COVID‐19) | MultiStem | Intravenously | 400, randomized | 2 | Recruiting |
| NCT03042143 | Repair of acute respiratory distress syndrome by Stromal Cell Administration (REALIST): An open label dose escalation phase 1 trial followed by a randomized, double‐blind, placebo‐controlled phase 2 trial (COVID‐19) | hUC‐MSCs | 4 × 108 cells Intravenously | 75, randomized | 1 | Recruiting |
| NCT04445220 | A multi‐center, randomized, case controlled, double‐blind, ascending‐dose study of extracorporeal mesenchymal Stromal Cell Therapy (SBI‐101 therapy) in COVID‐19 Subjects with acute kidney injury receiving renal replacement therapy | SBI‐101 using allogeneic MSCs | 250 × 106 cells (low dose) and 750 × 106 cells (high dose) | 22, randomized | 1 and 2 | Recruiting |
| NCT04336254 | Safety and efficacy study of allogeneic human dental pulp Mesenchymal Stem Cells to treat severe pneumonia of COVID‐19: a single‐center, prospective, randomised clinical trial | Allogeneic human dental pulp stem cells | 3.0 × 106 cells day 1, day 4 and day 7 intravenously | 20, randomized | 1 | Recruiting |
| NCT04392778 | What is the effect of Mesenchymal Stem Cell Therapy on seriously Ill patients With Covid 19 in intensive Care? | hUC‐MSCs intravenously | 3 × 106 cells/kg day 0, 3 and 6 Intravenously | 30, randomized | 1 | Recruiting |
| NCT04390152 | Safety and efficacy of intravenous infusion of Wharton's jelly derived Mesenchymal Stem Cell Plus standard therapy for the treatment of patients with acute respiratory distress syndrome diagnosis due to COVID 19: A randomized controlled trial | Wharton's jelly derived MSCs | 50 × 106 cells, two doses intravenously | 40, randomized | 1 | Recruiting |
| NCT04461925 | Treatment of Coronavirus COVID‐19 Pneumonia (pathogen SARS‐CoV‐2) with cryopreserved allogeneic multipotent Mesenchymal Stem Cells of the placenta and umbilical cord | Placenta‐derived MSCs | 1 × 106 cells/kg body weight time on day 1, 4 and 7 Intravenously | 30, non‐randomized | 1 | Recruiting |
| NCT04565665 | Emergency use pilot study of cord blood derived Mesenchymal Stem Cells for treatment of COVID‐19 Related acute respiratory distress syndrome | Cord blood‐derived MSCs | Single dose Intravenously | 70, randomized | 1 | Recruiting |
| NCT04252118 | Safety and efficiency of Mesenchymal Stem Cell in treating pneumonia patients infected With COVID‐19 | MSCs | 3.0 × 106 intravenously day 0, day 3, day 6 | 20, non‐randomized | 1 | Recruiting |
| NCT04611256 | Adjuvant therapy with Mesenchymal Stem Cells in patients diagnosed With COVID‐19 in critical condition | AD‐MSCs | 1 × 106/kg body weight Intravenously | 20, randomized | 1 | Recruiting |
| NCT04457609 | Application of umbilical cord Mesenchymal Stem Cells as adjuvant therapy for critically‐Ill COVID‐19 patients | UC‐MSCs | 1 × 106 cells/kg body weight intravenously | 40, randomized | 1 | Recruiting |
| NCT04397796 | Phase 1b Randomized, double‐blind, placebo‐controlled study of the safety of therapeutic treatment with immunomodulatory Mesenchymal Stem Cells In adults With COVID‐19 Infection requiring mechanical ventilation | BM‐Allo.MSC | ‐ | 45, randomized | 1 | Recruiting |